Table 1.

Xenograft erlotinib response results

TumorEGFRPTENMean*ΔMean (%)P
6+vIIIWild-type78/8250.536
12+Wild-type24/29210.027
15+Wild-type43/4550.683
34+Wild-type103/115120.860
39+vIIIWild-type88/121380.014
8+Null102/99−40.797
22Wild-type44/52180.226
44Wild-type71/61−140.362
14Null34/3530.732
28Null34/3660.191
36Null123/112−90.445
  • NOTE: Once a day administration (Monday to Friday), until symptomatic or for a maximum of 4 wks. Daily administration of 100 mg/kg for experiments with tumors 6, 8, 12, and 14; all others at 150 mg/kg daily.

  • * Mean values are in days; values to the left of each pair are for control groups, whereas values to the right are for erlotinib treatment groups. Equal numbers of control and treatment group mice were used in testing each xenograft, with not less than 5 nor more than 10 mice tested per group.

  • Percentage of change in mean survival between control and erlotinib treatment groups.

  • Results in boldface are for tumors showing sensitivity to erlotinib, as indicated by the significant (P < 0.05) survival benefit for erlotinib-treated mice.